Fredun Pharmaceuticals Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Hypergrowth narrative intact: Management reiterated blended growth of 30–35% for the next 3 years, driven by new brands, existing lines, and Palghar capacity additions.
• Q1 strength was partly a pull-forward: Higher Q1 FY27 growth came from carrying extra stock into the quarter and booking orders at old prices before increases, a boost that will not repeat.
• Wagr.in is the new growth engine: The pet parenting platform soft-launched mid-June, with brand and pharmacy onboarding nearly complete and campaigns due within 90 days.
• Margin expansion is promised, not dated: Management sees a "sudden spike" in profitability within 8–11 quarters as demographic reach completes, but declined to commit to a fixed timeline for 12–13% EBIT margins.
• What to watch next quarter: Whether Wagr.in beta testing completes and campaigns launch on schedule, whether Q2 growth holds near Q1 levels, and whether inventory days keep falling toward the 120-day target.

Growth Outlook & Trajectory

• Blended growth commitment: Management stated blended growth of around 30–35% for the next 3 years is "on the charts," driven by new brands, existing ones, and capacity increases at the company's own Palghar facility.
• Palghar capacity: Five plants in Palghar with around 43 manufacturing locations added; those products will give a very good boost to sales and product line in the coming 3 to 5 years.
• Manufacturing ambition: Goal by end of December 2028 or early 2029 is to be one of the largest manufacturing units at a single location in the country.
• Coming quarters: Management expects growth "somewhat around the same kind of numbers as Q1 FY27," with growth in all numbers coming from next quarter or the quarter after.
• Next year: Anticipating almost the same kind of growth in revenue next year.
• Next 2–3 years: Will be on the same kind of growth trajectory as right now.
• Hypergrowth phase: Next 4 years are a hypergrowth phase for new age products in pet care, mobility, nutra, and cosmetics.
• FY27 revenue: Target was somewhere around ₹800 crores; in line to achieve that and on track to overachieve.
• ₹1,000 crore revenue: Management declined to commit, saying "anything can be possible" but would not comment.

Medhora: "I would want to give our partners, our investors, our people who believe in us something and positive news at the end of the year rather than overpromise something."

Wagr.in: Pet Parenting Platform

• Acquisition and build-out: Company took over the website and company last year; spent 3–4 months creating the team with people who have built successful e-commerce platforms.
• Brand onboarding: Almost all brands onboarded; within next 20–25 days, practically every single big brand in the country will be onboarded.
• Pharmacy onboarding: Pharmacies onboarded; almost 1,500–2,000 product range of medical products available to order from various brands across companies.
• Soft launch: Soft launch around 15th June; already live with people ordering, but still creating a stronger back end.
• Services ecosystem: Already has list of breeders, trainers, groomers, dog walkers, doctors, plus own diagnostics; tying up with various blood collection for pet blood collection; creating profile and online portal for blood collection and blood donation for pets.
• Beta completion: Within next 60–65 days, all beta testing will be done.
• Campaigns and partnerships: Within next 90 days, campaigns coming out, partnership with various key players in the industry coming up.
• Website changes: Look and feel of website will be slightly different in next 60–90 days.
• 24/7 helpline: Creating a 24/7 helpline for pet parents.

Medhora: "It is not just an e-commerce platform. Many people have started now latching on to it and started changing their websites to calling pet parenting."

Pet Care & New Product Lines

• Pet care growth: 40% to 50% growth for next 3–4 years; growing at 40–50% year-on-year in pet care "is not a big thing, at least for the next 3 years"; further spurt expected once cat food and diagnostics revenues start adding.
• Cat food launch: Launching cat food by third quarter of this financial year, so around fourth quarter of this financial year.
• Cat food revenue target: Planning to be ₹100 crore within 3 years from launching or within 3.5 years from launching, with plants being built for increasing functional food capacity.
• Cat biscuits: Coming up with cat biscuits; will be second or third to have cat biscuit treats in the country; creating a functional line for cats in coming 6–7 months.
• Functional foods FY27: Around ₹18 crores to ₹24 crores to sell only functional foods.
• Functional foods traction: Jain variant has picked up very well in certain pockets and done exceptionally well; functional food response in all metros has been very good; normal biscuit range has got very good response in Tier 2, Tier 3, Tier 4 cities.
• Pet care diagnostics: India's first pet diagnostics center opened in Mumbai (Worli); one more starting in Malad; another center being created in Vashi.
• OEM plans: Will start OEM manufacturing for functional food capacity for other companies.
• Acquisitions: Certain acquisitions in line in pet care; some small, some big; will update investors and markets.
• Team structure: Every single division and business has a separate CEO in place with 10–25 years of experience; India's number 1 pet nutritionist is part of the team; cat team includes industry stalwarts.

Medhora: "We are not in the dumping game. So we want people to slowly take it. Any good growth is exponential in nature. We like to flatline, no problem."

Fredun GX

• Growth expectation: Expect 25% to 35% growth in this business YoY for the next 5 years; no anticipated hiccup because of very small base.
• Planning horizon: Planned for next 3.5 to 4 years; anything more than that, management would not want to comment. For next 4 years, can easily consider around 30% to 35% growth on the GX line.
• Market potential: Market potential is huge; some big companies doing thousands of crores of GX; pharma penetration itself is very poor in India even in 2026; in next 10 years, as India progresses and people come out of poverty line, even 1% of people is like a small country in Europe.
• Supply chain aim: Aim is to ensure supply chain is robust, products reach customers in time, and product basket keeps enhancing with latest molecules and further products.

Medhora: "We expect 25% to 35% growth in this business year-on-year, even for the next 5 years, we don't anticipate any hiccup because we are at a very small base."

Margins, Working Capital & Balance Sheet

• Margin mix: Different product lines carry different gross margins (pet care 45–55%, mobility 40–50%, nutrition 35–50%, dermaceutics 70–75%); blend of these margins helps improve bottom line; vintage business getting more efficient with new registrations in better geographies at higher margins.
• Margin improvement mechanism: Higher margins, better cash flows, and strong repeatability will reduce customer acquisition cost, improving gross margins and net margins "tremendously."
• Margin expansion philosophy: Focus for next few years is penetration, product acceptance, and conversion rates in repeat orders, not solely increasing profits; willing to sacrifice some margins for this.
• Profitability spike: Within next 8 to 11 quarters (management says "now around 7 to 8 quarters"), there will be a "sudden spike" in profitability because demographic reach will be almost completed as planned.
• EBIT margin 12–13%: Management would not commit to a fixed timeline; said within next 12 quarters "we should be probably near that number"; might do better, might take 1 quarter plus or minus.
• Working capital: Currently at ₹170–175 crores against ₹850 crore revenue run rate, which management characterizes as "not a high working capital for a company our size"; 50% of working capital is cash on hand.
• Working capital trajectory: Absolute working capital will increase at ₹2,000 crores or ₹3,000 crores of revenue, but in line with most manufacturing companies; goal is further positive cash flows to deter requirement of higher working capital from bankers.
• Interest costs: Interest costs are slowly reducing because cash flows are getting better and the company is using less of its limits; interest spending versus top line has "drastically reduced"; credit rating upgrade from BBB to BBB+ helped reduce interest rate further.
• Inventory rationalization: Inventory days have fallen by almost 50% in last 2 years; on 30–40% revenue growth, inventory only increases 10%, showing rationalization; high inventory historically was needed to bulk up for launching 5 brands with multiple SKUs across 2,100 products.
• Inventory target: Around 140–135 days now; within next 4 quarters, expected to come to around 120 days; will always hover between 110 to 125 days.
• CapEx: About ₹30–40 crores CapEx this financial year; same plan for next year; around ₹35–45 crores per year for next 2 years.
• Perpetual CapEx: Some CapEx will always be there for the plant perpetually because of constant facility/machinery upgrades and cGMP protocol requirements.

Q1 FY27 Performance Context

• Q1 seasonality: Q1 is historically the weakest of the four quarters because sales targets, import targets and distribution targets drive heavy purchasing in the last quarter; orders start rolling in around April end, so dispatches make Q1 optically weaker. However, Q1 has always improved versus the prior-year Q1.
• Q1 FY27 boost: Higher growth this Q1 came because during last year's last quarter, price fluctuation increases led the company to carry more stock; it could book orders at old prices with customers and got a better order book. The company told customers that further orders would get a lower price increase than the world was offering, giving a slight boost.
• Growth consistency: Management emphasized that growth has been consistent for the last 19 years, not just the last 3–4 years; highest growth was 110% YoY in 2008 and 115% YoY in 2009, but numbers were small then.
• Market expansion: Goal right now is to go into the market, add more states, add more demographics; next 3–4 years are "quite dynamic."
• Organization building: Management will "automatically form as a part of the process"; company will be better organized in next 5 to 7 years than now.

Medhora: "Though people are congratulating us for the numbers that we have shown this quarter, my highest growth was in 2008 and '09 when I've increased 110% year-on-year and 115% year-on-year. But because my numbers were so small, nobody congratulated me that time."

Guidance & Commitments

Key Metrics